Doug Dayhoff

Apr 8, 2024 | outsourcedpharma.com | Erich Bozenhardt |Doug Dayhoff |Incog BioPharma |Louis Garguilo

Don't get trapped in the misconception that only biomanufacturing process systems need maintenance. Here are some real-life examples of facility maintenance programs gone wrong. Inclusion Bodies: Mother Nature's Help Or Hindrance? The pros and cons of soluble and insoluble processes: isolating, solubilizing and properly refolding, and strategies to improve the performance of IB processes.

Aug 30, 2023 | outsourcedpharma.com | Louis Garguilo |Raj SHAH |KAMRUL HASAN |Doug Dayhoff

Chief editor Louis Garguilo's first experiences in outsourcing involved Japan, when Japan Pharma considered offshore CDMOs as too risky. He recently took a trip to Tokyo to report on the state of the biopharma-CDMO market there today. Monoclonal antibodies (mAbs) have emerged as a revolutionary class of therapeutic agents with the potential to treat various diseases.